BASF signs exclusive supply agreement with Caregen

Caregen’s highly potent synthetic peptides will be a complementary technology to the bioactives and other cosmetic solutions and ingredients offered by BASF’s personal care portfolio.

BASF has signed a global, exclusive supply agreement with Caregen, for four cosmetic peptides - anti-aging, anti-pigmentation, prone-atopic and prone-acneic skins to be launched in 2021.

“By using cosmetic products formulated with these peptides as active ingredients, consumers can have a choice of products with proven efficacy,” said Jeff Huh, Head of Marketing Personal Care Solutions at BASF Asia Pacific.

“Peptides are widely used as biological actives in different markets. Selecting the most promising peptides from Caregen’s huge portfolio and adapting them to the standards of the cosmetic industry has been a great achievement of our team,” said David Hérault, Head of Global Product Development Bio-actives at BASF Care Chemicals.

“Building on Caregen’s functional peptides with high technical and commercial competitiveness and BASF’s expertise in solutions and ingredients which are offered to the global cosmetics market, this agreement has both companies well set up for long-term cooperation,” said Dr. Chung Yong-Ji, CEO, Caregen.

Caregen’s highly potent synthetic peptides will be a complementary technology to the bioactives and other cosmetic solutions and ingredients offered by BASF’s personal care portfolio.